"We are very pleased to be partnering with the stellar leadership of the Department of Health -
The finalists were selected from a pool of exceptional candidates across more than 20 countries and represent a diverse range of companies and research institutions developing innovative therapeutic solutions. Each finalist has demonstrated a commitment to advancing healthcare through creativity and groundbreaking research, with the ultimate goal of addressing unmet patient need for diseases of prevalence in the
- Algen Biotechnologies,
Chun-Hao Huang , PhD, Co-Founder & CEO - AnaCardio, Patrik Strömberg, PhD, CEO
- Chimera Therapeutics,
Matthew Lorence , PhD, Co-Founder & CEO - Harmonic (NASDAQ:HLIT) Discovery (NASDAQ:WBD),
Rayees Rahman , PhD, CEO - Lactocore,
Anton Malyshev , PhD, Founder & CEO - Medicovestor, Seah Lim, PhD, CEO
- Oncoheroes Biosciences,
Cesare Spadoni , PhD, Co-Founder & COO - Paradox Immunotherapeutics,
Natalie Galant , PhD, Co-Founder & CEO - SaudiVax,
Mazen Hassanain , PhD, CEO - Ypsilon Therapeutics,
Dongxing Zha , PhD, Founder & CEO - ZTI Biosciences,
Jaden Hyungseok Chang , PhD, CEO
The finalists will be judged by an esteemed panel, which includes:
Laurie Glimcher , MD, President and CEO at Dana-Farber Cancer InstituteJorge Guzman , MD, CEO at Cleveland Clinic Abu Dhabi- Prof.
Shahrukh Khurshid Hashmi , Director of Research at Department of Health, Abu Dhabi David Hung , MD, Founder, President and CEO at Nuvation BioYasmine Hayek Kobeissi , PhD, CQF, BSc., Executive Director at Blue Horizon AdvisorsAnya Schiess , Managing Partner at J.P. Morgan Life Sciences Private Capital
"We are grateful to these preeminent scientists and business leaders for coming to
In addition to the pitch competition, where winners will ultimately be awarded, the summit will feature keynote speeches and networking opportunities to provide attendees with investment opportunities and valuable insights into the future of life sciences innovation. Learn more about the finalists and summit here.
About J.P. Morgan Life Sciences Private Capital
J.P. Morgan Life Sciences Private Capital is a venture capital and growth equity investment team within J.P. Morgan Global Alternatives, founded in late 2022. Life Sciences Private Capital launched its first early-stage biotechnology venture capital fund in early 2023, focused on building "move-the-needle" innovations that will ultimately improve quality of lives worldwide. The group aims to leverage J.P. Morgan's market position in healthcare investment banking and business banking, robust relationships with the largest pharmaceutical and life sciences companies, and the tenure of the Life Sciences Private Capital investment team and strategic advisors to form, capitalize, and support leading innovative life sciences companies.
For more information: J.P. Morgan Life Sciences Private Capital press release.
About J.P. Morgan Asset Management
J.P. Morgan Asset Management, with assets under management of
J.P. Morgan Asset Management is the marketing name for the asset management business of JPMorgan Chase & Co. (NYSE:JPM) and its investment advisor affiliates worldwide.
About Blue Horizon Advisors
Blue Horizon Advisors is the independent private investment arm of a leading, multi-billion dollar single
BHLS is committed to enhancing health through research and development of innovative therapies and diagnostic tools to improve and prolong lives. BHLS is poised to execute its strategic vision through a multifaceted approach, encompassing strategic acquisitions, robust in-house development initiatives, dynamic joint ventures with global industry leaders / innovators to foster knowledge exchange, and pivotal collaborations with key stakeholders in our ecosystem, including esteemed hospitals, renowned universities, regulatory authorities as well as local and global investment houses.